This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greenberg: What You May Have Missed

By: Herb Greenberg | 03/19/14 - 09:36 AM EDT

SAN DIEGO (TheStreet) -- Here's what you may have missed over the past week, including insight on Herbalife, Usana and a yellow flag on Twitter.

-- Twitter is Too Arcane

-- Putting Lipstick on Ulta

-- What to Expect from HLF Probe

-- Bizarre True Tale of Usana Stock Sales

-- Why World Acceptance Probe No Surprise

From my past week:

TWITTER IS TOO ARCANE: As Twitter (TWTR) tries to build growth in engaged users, I believe it needs to work on something else: making Twitter less arcane for new users. As I pointed out in a piece headlined "Twitter is Too Arcane," as Twitter pushes to the next level, if it wants to make itself appeal to the next-level of adopters it must make itself user friendly.

Engaged users, or monthly average users by timeline view, by the way, is perhaps the critical metric to watch when the company next reports earnings. Don't buy any of those, "but, look it's up so much from a year ago" comments (even though it isn't). This is a growth company, so it's got to show sequential growth -- from quarter to quarter -- not quarter over quarter. Any post-Oscar bump up, which was a promotional bonanza, should be viewed as a one-time event. No bump up would be nothing short of disconcerting.

Whenever I see its $28 billion valuation, which is well below its peak and not likely taking into account the full number of shares outstanding, assuming analyst are using the right number, all I can think of is how a year pre-IPO people were guessing that Twitter was valued at $10 billion, give or take a few billion. Since then, engaged users are down, the valuation is up, which is why, as much as I love Twitter, the service, I'm tossing it on my Reality Check Watch List with a yellow flag.


PUTTING LIPSTICK ON ULTA: Even after Ulta Salon (ULTA) reported guidance that missed the expectations, investors cheered the Reality Check Watch List stock because same-store sales were weak. But as I pointed out, EPS growth guidance is going the wrong direction, gross margins are at a two-year low, gross margin guidance has been abolished and inventory continues to soar versus revenue.


WHAT TO EXPECT FROM HERBALIFE PROBE: As the battle rages on over Herbalife (HLF), with the disclosure that the Federal Trade Commission is investigating the multi-level marketer, I make the case that even if Herbalife wins, it could still lose (as could Nu Skin (NUS), Usana (USNA) and the entire multi-level marketing industry.


BIZARRE TRUE TALES OF USANA STOCK SALES: Speaking of Usana, as I chronicle here in the annals of disclosure screw-ups, this one takes the cake and raises more questions than it answers. At issue is Chairman and founder Myron Wentz's filing of a Form 4 with the SEC that shows the sale of shares via stock-appreciation rights after the rights had expired. As I raised questions, over the course of days, the company started amending its Form 4s to show that the rights hadn't really expired, but that the expiration date had been extended last October, even though Usana, a Reality Watch List stock, had never filed any prior document showing an extension. Reality, my opinion only: Something's off here.


WHY WORLD ACCEPTANCE PROBE SHOULDN'T BE SURPRISING: As I wrote, the surprise would've been if the Consumer Financial Protection Bureau didn't investigate this 200% installment lender. Here's the best part. On Friday, after the market closed, the Stern Agee analyst sliced his price target on the stock to $75 from $105, slicing his price target on the basis that it's "waiting for CFPB issues to pass." Nothing like trying to sneak out through the back door. Oh, and for trivia buffs, the chairman of the audit committee at Conn's was, until late last year, the CFO of World.

-- Written by Herb Greenberg in San Diego

Herb Greenberg, editor of Herb Greenberg's Reality Check, is a contributor to CNBC. He does not own shares, short or trade shares in an individual corporate security. He can be reached at herbonthestreet@thestreet.com.

Other Posts In Herb's A Dose of Reality:

Get More Investment Ideas:

Cramer: It's the Tone That Makes the Music

07/23/14 - 11:39 AM EDT

Arnold: The End of Growth and Its Implications

07/23/14 - 10:05 AM EDT

Cramer: The James Dean Stocks

07/22/14 - 12:00 PM EDT

Williams: Shorting Tesla's Batteries

07/22/14 - 10:24 AM EDT

Gad: The Next Google-Like IPO

07/21/14 - 14:30 PM EDT

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Herb's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs